News

AstraZeneca will collaborate with Silence Therapeutics to discover, develop and commercialise small interfering RNA (siRNA) therapeutics for the treatment of Cardiovascular, Renal,…
Read More...

Sorrento Therapeutics, Inc. announced it has been working on a novel decoy cellular vaccine for COVID-19 (STI-6991) and is in active discussions with the FDA’s Center for Biologics…
Read More...

Forge Therapeutics, Inc. (Forge) announced that they have entered into a research collaboration and option agreement with Hoffmann-La Roche Ltd. (Roche) to license FG-LpxC LUNG, a novel…
Read More...

Grifols announces that it has entered into a formal collaboration with the United States Biomedical Advanced Research Development Authority (BARDA), the Food and Drug Administration…
Read More...

Debiopharm announced having entered into a worldwide, exclusive license & research agreement with 3B Pharmaceuticals (3BP), a German biotechnology firm, to further the development…
Read More...

Xencor, Inc. announced that it has entered into a technology license agreement with Vir Biotechnology, Inc., in which Vir will have non-exclusive access to Xencor’s Xtend Fc technology…
Read More...

Infinity Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IPI-549 in combination with nivolumab (Opdivo) for the…
Read More...

Alvotech Hf and DKSH, a leading healthcare provider across 36 emerging countries in South-East Asia, announced that Alvotech Hf and DKSH have entered into an exclusive license…
Read More...

CytomX Therapeutics, Inc. and Astellas Pharma Inc. announced that they have entered into a strategic collaboration agreement focused on the discovery, research, development and…
Read More...

Novavax, Inc. announced positive top-line results of its pivotal Phase 3 clinical trial of NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with its…
Read More...

Vaccitech Limited and the University of Oxford announce initial efficacy and safety data for ADVANCE, a Phase 2a study testing VTP-800, an immunotherapeutic product candidate in…
Read More...

ProBioGen AG announced that Immunogenesis, Inc., a spin-off of the MD Anderson Cancer Center, University of Texas, has signed a Service Agreement for Cell Line Development, Process…
Read More...

AbbVie announced the VIALE-A (M15-656) trial of VENCLEXTA (venetoclax) in combination with azacitidine versus azacitidine in combination with placebo met its dual primary endpoints of…
Read More...

Hoth Therapeutics, Inc. announced that it has reached an agreement with Voltron Therapeutics, Inc. (Voltron) to form a joint venture entity, to be named HaloVax, to commence preclinical…
Read More...

In response to the government call for rapidly deployable countermeasures, Sorrento Therapeutics, Inc. and SmartPharm Therapeutics Inc. (SmartPharm) announced a research and development…
Read More...

Flexipharm Austrading, the UK specialty pharmaceutical company focused on supplying the NHS with Better, Critical Care Medicines, announced an important improvement to the 'Summary of…
Read More...

Bayer and Curadev Pvt. Ltd., a drug discovery company based in India, announced a research collaboration and license agreement for Curadev’s Stimulator of Interferon Genes (STING)…
Read More...

Takeda Pharmaceutical Company Limited has announced that the gut-selective biologic Entyvio (vedolizumab) was approved by China’s National Medical Products Administration (NMPA). The…
Read More...

Genentech, a member of the Roche Group announced that the Phase III VIALE-A study met its dual primary endpoints of overall survival and composite complete remission rate (CR + CRi).…
Read More...

Genentech, a member of the Roche Group announced that the U.S. Food & Drug Administration (FDA) has approved a randomized, double-blind, placebo-controlled Phase III clinical trial…
Read More...